Valuation dashboard for Marker Therapeutics, Inc. (MRKR) with P/E N/A, P/B 1.56, EV/EBITDA -0.54 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology.
Valuation Ratios
| Price / Book | 1.56 |
| EV / EBITDA | -0.54 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| MRKR | Marker Therapeutics, Inc. | $19M | 1.56 | -72.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.14 |
| Market Cap | $19M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -72.42% |
| Return on Invested Capital | -76.65% |
| Return on Assets | -63.78% |
| Gross Margin | -320.83% |
| Operating Margin | -868.95% |
| Net Margin | -706.23% |
Explore sector: Healthcare · Biotechnology
More sections of MRKR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks